Loading…
Treatment outcome of superficial leiomyosarcoma
Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean...
Saved in:
Published in: | Journal of surgical oncology 2021-01, Vol.123 (1), p.127-132 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3 |
container_end_page | 132 |
container_issue | 1 |
container_start_page | 127 |
container_title | Journal of surgical oncology |
container_volume | 123 |
creator | Wellings, Elizabeth P. Tibbo, Meagan E. Rose, Peter S. Folpe, Andrew L. Houdek, Matthew T. |
description | Background
Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
Methods
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
Results
The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03).
Conclusions
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care. |
doi_str_mv | 10.1002/jso.26262 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2451848721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2472771629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</originalsourceid><addsrcrecordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdvJ526OUvyk0IP1HNJsAlt2m5rsIv33Rrd6EGQOc5iHl-FF6BLDFAOQ2Sb6KRFpjtAYgxS5BFkeo3G6kZwVEkboLMYNAEgp2CkaUQqCUirGaLYKVnet3XaZ7zvjW5t5l8V-Z4OrTa2brLG1b_c-6pCu-hydON1Ee3HYE_T2cL-aP-WL5ePz_G6RG8opySnlBa4YoUQaYzCrtMGlBqoNdwwqDsLZZNalJBo7YgnTHBdUANegJVnTCboZcnfBv_c2dqqto7FNo7fW91ERxnHJyoLgRK__0I3vwzZ9l1RBigILIpO6HZQJPsZgndqFutVhrzCorxZValF9t5js1SGxX7e2-pU_tSUwG8BH3dj9_0nq5XU5RH4CSMV5lw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472771629</pqid></control><display><type>article</type><title>Treatment outcome of superficial leiomyosarcoma</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</creator><creatorcontrib>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</creatorcontrib><description>Background
Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
Methods
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
Results
The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03).
Conclusions
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.26262</identifier><identifier>PMID: 33063336</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>dermal ; Female ; Follow-Up Studies ; Humans ; Incidence ; leiomyosarcoma ; Leiomyosarcoma - pathology ; Leiomyosarcoma - surgery ; Male ; Margins of Excision ; Medical prognosis ; Middle Aged ; Minnesota - epidemiology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; outcome ; Postoperative Complications - epidemiology ; Postoperative Complications - mortality ; Postoperative Complications - pathology ; Prognosis ; Retrospective Studies ; subcutaneous ; superficial ; Survival Rate</subject><ispartof>Journal of surgical oncology, 2021-01, Vol.123 (1), p.127-132</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</citedby><cites>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</cites><orcidid>0000-0003-0390-1018</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33063336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wellings, Elizabeth P.</creatorcontrib><creatorcontrib>Tibbo, Meagan E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><creatorcontrib>Houdek, Matthew T.</creatorcontrib><title>Treatment outcome of superficial leiomyosarcoma</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background
Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
Methods
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
Results
The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03).
Conclusions
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</description><subject>dermal</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Incidence</subject><subject>leiomyosarcoma</subject><subject>Leiomyosarcoma - pathology</subject><subject>Leiomyosarcoma - surgery</subject><subject>Male</subject><subject>Margins of Excision</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Minnesota - epidemiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>outcome</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - mortality</subject><subject>Postoperative Complications - pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>subcutaneous</subject><subject>superficial</subject><subject>Survival Rate</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdvJ526OUvyk0IP1HNJsAlt2m5rsIv33Rrd6EGQOc5iHl-FF6BLDFAOQ2Sb6KRFpjtAYgxS5BFkeo3G6kZwVEkboLMYNAEgp2CkaUQqCUirGaLYKVnet3XaZ7zvjW5t5l8V-Z4OrTa2brLG1b_c-6pCu-hydON1Ee3HYE_T2cL-aP-WL5ePz_G6RG8opySnlBa4YoUQaYzCrtMGlBqoNdwwqDsLZZNalJBo7YgnTHBdUANegJVnTCboZcnfBv_c2dqqto7FNo7fW91ERxnHJyoLgRK__0I3vwzZ9l1RBigILIpO6HZQJPsZgndqFutVhrzCorxZValF9t5js1SGxX7e2-pU_tSUwG8BH3dj9_0nq5XU5RH4CSMV5lw</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Wellings, Elizabeth P.</creator><creator>Tibbo, Meagan E.</creator><creator>Rose, Peter S.</creator><creator>Folpe, Andrew L.</creator><creator>Houdek, Matthew T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0390-1018</orcidid></search><sort><creationdate>202101</creationdate><title>Treatment outcome of superficial leiomyosarcoma</title><author>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>dermal</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Incidence</topic><topic>leiomyosarcoma</topic><topic>Leiomyosarcoma - pathology</topic><topic>Leiomyosarcoma - surgery</topic><topic>Male</topic><topic>Margins of Excision</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Minnesota - epidemiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>outcome</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - mortality</topic><topic>Postoperative Complications - pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>subcutaneous</topic><topic>superficial</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wellings, Elizabeth P.</creatorcontrib><creatorcontrib>Tibbo, Meagan E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><creatorcontrib>Houdek, Matthew T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wellings, Elizabeth P.</au><au>Tibbo, Meagan E.</au><au>Rose, Peter S.</au><au>Folpe, Andrew L.</au><au>Houdek, Matthew T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment outcome of superficial leiomyosarcoma</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>123</volume><issue>1</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS.
Methods
We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy.
Results
The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03).
Conclusions
The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33063336</pmid><doi>10.1002/jso.26262</doi><tpages>0</tpages><orcidid>https://orcid.org/0000-0003-0390-1018</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-4790 |
ispartof | Journal of surgical oncology, 2021-01, Vol.123 (1), p.127-132 |
issn | 0022-4790 1096-9098 |
language | eng |
recordid | cdi_proquest_miscellaneous_2451848721 |
source | Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list) |
subjects | dermal Female Follow-Up Studies Humans Incidence leiomyosarcoma Leiomyosarcoma - pathology Leiomyosarcoma - surgery Male Margins of Excision Medical prognosis Middle Aged Minnesota - epidemiology Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery outcome Postoperative Complications - epidemiology Postoperative Complications - mortality Postoperative Complications - pathology Prognosis Retrospective Studies subcutaneous superficial Survival Rate |
title | Treatment outcome of superficial leiomyosarcoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20outcome%20of%20superficial%20leiomyosarcoma&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Wellings,%20Elizabeth%20P.&rft.date=2021-01&rft.volume=123&rft.issue=1&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.26262&rft_dat=%3Cproquest_cross%3E2472771629%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2472771629&rft_id=info:pmid/33063336&rfr_iscdi=true |